Dr. Agarwal’s Health Care Limited announced a significant 20.8% YoY increase in total income, reaching ₹1,548 Crores for the nine months ended December 31, 2025. The company’s IND-AS EBITDA also grew by 23.6% YoY to ₹440 Crores. Profit after tax (PAT) saw an impressive surge of 74.3% YoY, climbing to ₹118 Crores, driven by robust growth in revenues and improved operational efficiencies.
Financial Performance Highlights
Dr. Agarwal’s Health Care Limited reported strong financial results for the quarter and nine months ended December 31, 2025 (Q3 FY2026):
- Total income soared by 20.8% YoY to ₹1,548 Crores.
- IND-AS EBITDA grew by 23.6% YoY to ₹440 Crores.
- PAT surged by 74.3% YoY to ₹118 Crores.
Key figures for Q3 FY2026 include:
- Total Income: ₹540 Crores, a 21.9% YoY growth.
- Revenue from Operations: ₹530 Cr, growing by 23.0% YoY.
- EBITDA: ₹155 Cr, up by 21.3% YoY, with EBITDA margins of 28.6%.
- Profit after Tax: ₹44 Cr, a 54.5% YoY increase with after-tax margins of 8.1%.
Operational Growth and Network Expansion
As of December 31, 2025, Dr. Agarwal’s network expanded to 272 facilities across 10 countries, including 14 new centers during the quarter (9 secondary and 5 primary facilities). The company performed 81,002 surgeries in Q3 FY2026, reflecting a growth of 11.2% YoY.
Strategic Initiatives
Dr. Agarwal’s Health Care Limited is undertaking several strategic initiatives:
- Incorporation of a Wholly Owned Subsidiary in Ethiopia: Orbit Healthcare Services (Mauritius) Limited is in the process of incorporating a wholly-owned subsidiary in Ethiopia, enhancing the company’s presence in Africa.
- Shifting of Registered Office: The registered and corporate office is being shifted to a new location in Chennai to facilitate better administrative convenience.
- Amendment to Shareholders Agreement of Idearx: Idearx Services Private Limited will cease to be an associate company as the objectives of the shareholder’s agreement have been realized.
Leadership Commentary
Dr. Adil Agarwal, CEO, commented on the company’s strong performance, highlighting the robust growth in revenues and profitability, driven by healthy patient volumes and strong traction across mature centers.
Source: BSE
